中国创新药表现亮眼，创新药ETF国泰（517110）飘红，连续3日迎净流入

Core Insights - The 2025 ESMO conference highlighted the strong performance of Chinese innovative drugs, with 448 research abstracts representing 15.3% of the total, including 35 oral presentations and 23 latest breakthrough abstracts (LBA), showcasing China's leadership in global pharmaceutical R&D [1] Industry Summary - Chinese pharmaceutical companies demonstrated international competitiveness in key areas such as ADC, bispecific/multispecific antibodies, and immunotherapy combination treatments, establishing China as the largest source of innovative drug patents outside the United States [1] Company Summary - The Guotai Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which selects innovative drug companies from the Shanghai, Shenzhen, and Hong Kong markets, focusing on R&D-driven firms. This index reflects the overall performance of China's innovative drug industry, emphasizing high growth potential and industry concentration [1]